Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular pathology of non-invasive urothelial carcinomas (part I).

Literature DB >> 12715166

Molecular pathology of non-invasive urothelial carcinomas (part I).

Burkhard Helpap¹, Bernd J Schmitz-Dräger, Peter W Hamilton, Giovanni Muzzonigro, Andrea B Galosi, Karl H Kurth, David Lubaroff, David J Waters, Michael J Droller.

Abstract

An international consultation on the diagnosis of non-invasive urothelial neoplasms was held in Ancona, Italy in May 2001. Besides histology and problems of classification, one group of experts (Committee no. 3) discussed the molecular pathology and cytometry of non-invasive urothelial carcinomas. In the following first part, special immunohistochemical and molecular markers for stratifications in bladder cancer were discussed including different cytokeratins (clone 34betaE12, CK 20), cell proliferation markers (Ki67/MIB-1, PCNA, AgNOR, DNA-cytometry), tumor suppressor genes and oncogenes (p53, p21, erb-B2, bcl-2), different receptor expressions of epidermal growth factor and vascular endothelial growth factor and others. These molecular markers were analyzed in diagnosis of urothelial carcinomas, recurrences, progression and response to treatment.

Entities: Disease Gene

Mesh：

Substances：

Year: 2003 PMID： 12715166 DOI： 10.1007/s00428-002-0748-0

Source DB: PubMed Journal: Virchows Arch ISSN： 0945-6317 Impact factor: 4.064

52 in total

1. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.

Authors: T S Tzai; N H Chow; J S Lin; W H Yang; Y C Tong
Journal: Anticancer Res Date: 1998 Nov-Dec Impact factor: 2.480

2. p53 and RB expression predict progression in T1 bladder cancer.

Authors: H B Grossman; M Liebert; M Antelo; C P Dinney; S X Hu; J L Palmer; W F Benedict
Journal: Clin Cancer Res Date: 1998-04 Impact factor: 12.531

3. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.

Authors: P U Malmström; H Wijkström; C Lundholm; K Wester; C Busch; B J Norlén
Journal: J Urol Date: 1999-04 Impact factor: 7.450

4. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.

Authors: G Casetta; P Gontero; R Russo; D Pacchioni; A Tizzani
Journal: Eur Urol Date: 1997 Impact factor: 20.096

5. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.

Authors: A R Zlotta; J C Noel; I Fayt; A Drowart; J P Van Vooren; K Huygen; J Simon; C C Schulman
Journal: J Urol Date: 1999-03 Impact factor: 7.450

6. Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer.

Authors: M Caliskan; L N Türkeri; B Mansuroglu; G Toktas; B Aksoy; E Unlüer; A Akdas
Journal: Br J Urol Date: 1997-03

7. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder.

Authors: A S Sarkis; G Dalbagni; C Cordon-Cardo; J Melamed; Z F Zhang; J Sheinfeld; W R Fair; H W Herr; V E Reuter
Journal: J Urol Date: 1994-08 Impact factor: 7.450

8. P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder.

Authors: D J Thomas; M C Robinson; R Charlton; S Wilkinson; B K Shenton; D E Neal
Journal: Br J Urol Date: 1994-05

9. [Monoclonal antibodies (MIB 1, PC 10, 486p and p53) as prognostic factors for recurrent urothelial carcinoma of the urinary bladder].

Authors: R Hake; R Vorreuther; P Borchmann; S Lukowsky; J Thiele; R Fischer
Journal: Verh Dtsch Ges Pathol Date: 1993

10. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

Authors: A S Sarkis; G Dalbagni; C Cordon-Cardo; Z F Zhang; J Sheinfeld; W R Fair; H W Herr; V E Reuter
Journal: J Natl Cancer Inst Date: 1993-01-06 Impact factor: 13.506

8 in total

Review 1. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. A joint proposal of the European Society of Uropathology and the Uropathology Working Group.

Authors: Antonio Lopez-Beltran; Pier Francesco Bassi; Michele Pavone-Macaluso; Rodolfo Montironi
Journal: Virchows Arch Date: 2004-06-08 Impact factor: 4.064

2. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.

Authors: A Quintero; J Alvarez-Kindelan; R J Luque; R Gonzalez-Campora; M J Requena; R Montironi; A Lopez-Beltran
Journal: J Clin Pathol Date: 2006-01 Impact factor: 3.411

3. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases.

Authors: Eva Compérat; Philippe Camparo; Rachel Haus; Emmanuel Chartier-Kastler; Stephane Bart; Annick Delcourt; Alain Houlgatte; Richard François; Fréderique Capron; Annick Vieillefond
Journal: Virchows Arch Date: 2005-11-08 Impact factor: 4.064

4. Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms.

Authors: E Compérat; P Camparo; R Haus; E Chartier-Kastler; B Radenen; F Richard; F Capron; V Paradis
Journal: Virchows Arch Date: 2007-02-28 Impact factor: 4.064